HUMAN T-CELL LEUKEMIA VIRUS (HTLV) ANTIBODIES IN MYCOSIS FUNGOIDES AND LEUKEMIAS AND LYMPHOMAS

Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

HUMAN T-CELL LEUKEMIA VIRUS (HTLV) ANTIBODIES IN MYCOSIS FUNGOIDES AND LEUKEMIAS AND LYMPHOMAS

Dev Oncol; 28:247-53 1985. Unique Identifier : AIDSLINE ICDB/86621740
Srivastava BI; Koga M; Roswell Park Memorial Inst., Buffalo, NY 14263

Abstract: Patients (pts) with mycosis fungiodes/Sezary syndrome (MF/SS) or various leukemias/lymphomas were examined for the presence of human T-cell leukemia virus (HTLV) antibodies. HTLV antibodies in serum/plasma and HTLV p-19 antigen expression by cells were assessed in 108 subjects. About 25% of pts with MF/SS and 10% (ELISA assay) to 20% (immunofluorescence (IF) assay) with common forms of leukemias/lymphomas had antibodies to HTLV, a figure significantly higher than the less than 1% observed in the US general population. Leukocytes of five of the 17 HTLV-positive individuals were also positive for HTLV p-19 antigen. Among 17 HTLV antibody positives by the IF test, 8 were also positive by ELISA assay (4 MF/SS pts, 4 leukemia/lymphoma pts). Of 12 pts with leukemia/lymphoma who were HTLV-positive, 7 had received blood products, and 5 had not, but at least 2 in each of these latter groups were positive in both ELISA assay and IF assay. No MF/SS pts had received a blood transfusion. Blood transfusion, although a possible source of HTLV-antibody positivity in some cases, cannot be the source for those pts who did not receive it. An alternative source of HTLV infection in common leukemia/lymphoma pts, who generally are immunosuppressed, could be secondary or opportunistic infection; or, HTLV or a variant virus might have some role in these malignancies, but be expressed rarely, as in cutaneous T-cell lymphomas. (3 Refs)

Keywords: Adolescence Adult Aged Antibodies, Viral/*ANALYSIS Antigenic Determinants/IMMUNOLOGY Antigens, Viral/IMMUNOLOGY Child Enzyme-Linked Immunosorbent Assay Female Fluorescent Antibody Technique Human HTLV-BLV Viruses/IMMUNOLOGY Leukemia/*IMMUNOLOGY Lymphoma/*IMMUNOLOGY Male Middle Age Mycosis Fungoides/*IMMUNOLOGY Retroviridae Infections/*IMMUNOLOGY Sezary Syndrome/IMMUNOLOGY MEETING PAPER

861130
M86B0248

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .